Recce Pharmaceuticals (ASX:RCE) 3-Year Book Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RCE Recce Pharmaceuticals Ltd ASX:RCE
20 GF Score
Price A$0.36
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals 3-Year Book Growth Rate?

Recce Pharmaceuticals ASX:RCE 20 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 1,128 Biotechnology companies, Recce Pharmaceuticals ranks worse than 88652.39% on this metric.

Recce Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2025 was A$-0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Recce Pharmaceuticals was 143.80% per year. The lowest was 34.40% per year. And the median was 89.10% per year.

Recce Pharmaceuticals  (ASX:RCE) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Recce Pharmaceuticals 3-Year Book Growth Rate Related Terms

ASX:RCE vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, Recce Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's 3-Year Book Growth Rate falls into.


ASX:RCE
20GF Score
Recce Pharmaceuticals Ltd ASX:RCE
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Recce Pharmaceuticals (ASX:RCE) has a 3-Year Book Growth Rate of 0.00% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Recce Pharmaceuticals and its competitors. Over the past decade, Recce Pharmaceuticals' 3-Year Book Growth Rate has ranged from 34.40 to 143.80. According to the industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 1128 companies in the Biotechnology industry.
Is Recce Pharmaceuticals' 3-Year Book Growth Rate too high?
Recce Pharmaceuticals' current 3-Year Book Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 34.40 to a high of 143.80. Based on the distribution chart, Recce Pharmaceuticals ranks #999999 out of 1128 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #999999 out of 1128 companies for 3-Year Book Growth Rate. This places Recce Pharmaceuticals in the lower half of its industry. Historically, Recce Pharmaceuticals' own 3-Year Book Growth Rate has ranged from 34.40 to 143.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Recce Pharmaceuticals' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current 3-Year Book Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:Germany
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
20GF Score

Get the complete analysis for ASX:RCE

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.36
Price